![metastic melanoma cells](https://www.uc.edu/news/articles/2024/04/n21244388/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1713369777174.jpg)
Medscape: Skin adverse events rare after immunotherapy to treat skin cancers
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found certain skin adverse events were rare following immunotherapy treatments for certain skin cancers.
"Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors are commonly used drugs for the treatment of various cancers," said Pushkar Aggarwal, MD, corresponding author and medical resident/fellow in UC's College of Medicine. "Having knowledge regarding possible associated skin reactions is vital for clinicians to guide management of the skin reaction and whether an adjustment is needed for the PD-1/PD-L1 inhibitors."
The researchers reviewed adverse event reports for patients treated with PD-1 and PD-L1 treatments between January 2004 and May 2023 to identify whether significant signals exist between PD-1/PD-L1 inhibitors and skin tumors keratoacanthoma and cutaneous squamous cell carcinoma (cSCC).
"For both keratoacanthoma and cSCC, significant signals were found with PD-1/PD-L1 inhibitors," Aggarwal said. But, out of 158,000 cases in the review, the data showed only 43 patients developing keratocanthoma and 83 developing cSCC, which highlights the conditions are "relatively rare adverse events."
Aggarwal said case reports, case-control trials and randomized clinical trials are needed to confirm the results of this study.
Featured photo at top of metastatic melanoma cells. Photo/National Cancer Institute.
Related Stories
Medscape: Skin adverse events rare after immunotherapy to treat skin cancers
April 17, 2024
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found skin adverse events were rare following immunotherapy treatments for certain skin cancers.
Physics World names UC, Cincinnati Children's study among top 10 Breakthroughs of 2022
December 8, 2022
Physics World recognized the University of Cincinnati's first-in-human trial of FLASH radiotherapy as one of the Top 10 Breakthroughs of the Year for 2022.
GEN News: Biomarker discovery to help predict breast cancer outcomes
September 7, 2022
GEN News highlighted recent University of Cincinnati and Cincinnati Children's Hospital Medical Center research on metabolic signatures that help predict breast cancer outcomes and could open avenues for new treatments.
Local 12, Business Courier highlight Blood Cancer Healing Center
February 19, 2024
Local 12 and the Cincinnati Business Courier highlighted the University of Cincinnati Cancer Center's Blood Cancer Healing Center, a comprehensive all-in-one facility dedicated solely to advancing research, treatment and wellness for blood cancer patients, opening this summer.
Media highlight UC's FLASH radiotherapy trial
October 25, 2022
National media outlets highlighted the results of the first-in-human trial of FLASH radiotherapy, led by University of Cincinnati Cancer Center researchers.
Medium highlights UC research of light as treatment for cancer
August 10, 2022
Medium featured the research of the University of Cincinnati's Jiajie Diao, PhD, who recently published a paper showing early results that light-activated proteins can help normalize dysfunction within cells.
Pennsylvania news: Personalized treatment for deadly blood and bone marrow cancer
April 26, 2023
WFMZ-TV in Allentown, Pennsylvania highlighted the University of Cincinnati's John Byrd and the Beat AML study testing personalized treatment for patients with acute myelogenous leukemia.
U.S. News: Could gut microbes affect pancreatic cancer survival?
April 6, 2023
U.S. News and World Report highlighted research led by the University of Cincinnati's Jordan Kharofa that found several enriched species, associated with enhanced tumor immune response, in the microbiomes of long-term pancreatic cancer survivors.
Yahoo News: UC researchers aim to offer more cancer treatment options for patients
September 16, 2022
WLWT and Yahoo News highlighted work being done by University of Cincinnati Cancer Center researchers to advance cancer care through new immunotherapy and cellular therapy treatments.
Medical News Today: Gene mutation may be a key to lung cancer treatment
September 21, 2022
Medical News Today highlighted recent research led by the University of Cincinnati's Pier Paolo Scaglioni, MD, that found targeting components of lipid metabolism and synthesis could lead to an effective lung cancer treatment.